<p><strong>Ask any analytical chemist which hyphenated technique has become indispensable over the past decade, and the answer will almost certainly be the same: tandem chromatography–mass spectrometry. Whether it is </strong><a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis"><strong>LC–MS/MS</strong></a><strong> quantifying a novel biologic’s metabolic fate, or </strong><a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-gc-ms/ms-analysis"><strong>GC–MS/MS</strong></a><strong> chasing per- and polyfluoroalkyl substances (PFAS) down to sub-part-per-trillion levels in municipal water, the combination of chromatographic separation with the specificity of tandem mass detection has become the analytical workhorse of choice across virtually every regulated sector.</strong></p><p>Below we examine the key forces propelling this expansion, from biopharma pipeline dynamics and PFAS regulatory mandates to AI-driven automation and reshoring of pharmaceutical manufacturing—and explore what each trend means for laboratories managing sample preparation and analytical workflows.</p><h3><strong>Biopharma: The Engine Room of LC–MS/MS Demand</strong></h3><h4><strong>GLP-1 Agonists and the Metabolomics Gold Rush</strong></h4><p>The explosive commercial and scientific interest in GLP-1 receptor agonists—<a target="_blank" rel="noopener noreferrer" href="https://www.sepscience.com/advancing-glp-1-peptide-analysis-chromatography-challenges-and-innovations-12163"><strong>semaglutide and related peptide therapeutics </strong></a>for diabetes and obesity—has dramatically expanded the analytical demands placed on tandem MS platforms. Discovery programs require precise quantification of peptide drug candidates and endogenous biomarkers across complex biological matrices. These workflows rely on high-sensitivity LC–MS/MS for pharmacokinetic profiling, receptor occupancy studies, and metabolomics characterization. Metabolomics is, in fact, projected to be the fastest-growing application segment in mass spectrometry, driven in part by its growing role in cancer screening, biomarker discovery, and metabolic disease research.</p><p>I have been spending more time learning about GLP-1s because this is the hot topic that people want to discuss on the Concentrating on <a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL?si=n9GLz9zjSCOrVfXPxFPhng&amp;nd=1&amp;dlsi=52868e027aad4d22"><strong>Chromatography podcast</strong></a>. With that said, I was astounded looking at CNBC.com during breakfast this morning to see that <a target="_blank" rel="noopener noreferrer" href="https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html"><strong>one in eight Americans are currently taking one of these drugs such as Ozempic</strong></a>.</p><h4><strong>Antibody–Drug Conjugates and Gene Therapy: Complexity at Every Step</strong></h4><p>The ascent of antibody–drug conjugates (ADCs) and gene therapies has introduced a new level of analytical complexity. ADCs blend the target specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads—and characterizing the linker chemistry, drug-to-antibody ratio (DAR), and conjugate stability demands high-resolution LC–MS/MS at every stage from discovery through QC release testing. Gene therapy vectors require equally rigorous characterization of impurities, aggregates, and empty/full capsid ratios.</p><p>This translates into a direct need for low-evaporation, high-recovery concentration methods that preserve labile protein structures and maintain sample integrity prior to LC–MS/MS injection. <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5392"><strong>Nitrogen evaporation workflows</strong></a> that minimize oxidative stress and maintain sample temperature are increasingly critical in these pipelines.</p><h4><strong>Precision Medicine and Multi-Omics Integration</strong></h4><p>The shift toward precision medicine has accelerated adoption of high-throughput, multi-analyte MS platforms. Proteomics, metabolomics, and lipidomics workflows are converging on a single analytical platform—tandem MS—and generating datasets of a scale and complexity that were unimaginable ten years ago.</p><p>Make no mistake: the triple quadrupole serves an irreplaceable role in quantitative targeted analysis. At the same time, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=134&amp;manufacturerItems=3"><strong>Orbitrap </strong></a>and <strong>Q–TOF</strong> hybrid platforms are growing rapidly as researchers demand full-scan accurate mass for untargeted discovery.</p><h3><strong>Environmental Mandates: PFAS Testing Drives Adoption</strong></h3><p>Environmental testing is something that every person, chemist or not, can understand the importance of. Mounting mandates from the U.S. Environmental Protection Agency and European regulators regarding PFAS—the “forever chemicals” whose extraordinary environmental persistence is matched only by the analytical challenge of detecting them at trace levels—have created immediate, compliance-driven investment in LC–MS/MS infrastructure.</p><h4><strong>The Regulatory Framework Chemists Need to Know</strong></h4><p>The EPA has codified a suite of LC–MS/MS-based methods as the analytical standard for PFAS in water and solid matrices:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/epa-533-drying-down-pfas-samples-after-spe"><strong>EPA Method 533</strong></a><strong>:</strong> Weak anion exchange SPE combined with LC–MS/MS; covers 25 PFAS including short-chain compounds in drinking water.</li><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/sample-concentration-epa-method-537-pfas-determination"><strong>EPA Method 537.1</strong></a><strong>: </strong>Reversed-phase SPE followed by LC–MS/MS; covers 18 PFAS including the GenX compound, with method detection limits in the low ng/L range.</li><li><a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/en/solutions/environmental/water-testing/pfas-in-water/us-epa-method-8327?srsltid=AfmBOooCY1pcavj7B1PH-75d3HO4BGDglNlhmyTyrpDY3zvUksMO1dlg"><strong>EPA Method 8327</strong></a><strong>: </strong>LC–MS/MS for selected PFAS in prepared extracts of aqueous and solid matrices.</li><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/preparing-diverse-sample-matrices-for-epa-method-1633"><strong>EPA Draft Method 1633</strong></a><strong>: </strong>The emerging benchmark for PFAS in non-aqueous matrices—aqueous, solid, biosolids, and tissue—quantifying up to 40 PFAS.</li></ul><p>All of these methods designate LC–MS/MS, specifically LC coupled to triple quadrupole or tandem-in-time platforms operating in negative electrospray ionization mode with multiple reaction monitoring (MRM), as the required or recommended analytical technique. PFAS analysis is, at its core, an LC–MS/MS problem.</p><h4><strong>The Sample Preparation Bottleneck</strong></h4><p>Chemists who have worked with PFAS methods understand the particular demands they place on sample preparation. The ubiquity of<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/tackling-pfas-contamination-practical-insights-from-epa-537.1-method-development"><strong> PFAS in laboratory materials</strong></a>—PTFE tubing, some SPE sorbents, standard bench supplies—means that blank contamination control is as analytically demanding as the detection itself. EPA 537.1 requires that sample volumes of approximately 250 mL be extracted and reconstituted in as little as 1 mL, creating a 250:1 concentration factor that can expose even trace contamination in the sample processing chain. The installation of a delay column between the LC pump and autosampler to prevent instrument background interference is now standard practice.</p><p>This is precisely where robust, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5385"><strong>inert nitrogen evaporation </strong></a>systems earn their keep. PFAS workflows that use nitrogen-assisted evaporation to concentrate extracts prior to reconstitution benefit from materials that avoid PTFE and other fluoropolymers that can leach PFAS background—a consideration Organomation addresses in its concentration system designs.</p><p>The analytical community is also moving beyond targeted PFAS analysis. High-resolution accurate mass (HRAM) spectrometry via Orbitrap technology, paired with non-targeted screening workflows, is gaining traction for the identification of the more than 5,000 currently catalogued PFAS compounds and the novel structures that continue to emerge. LC–MS/MS remains the quantitative gold standard; HRAM provides the discovery layer.</p><h3><strong>Technological Trends Reshaping the LC–MS/MS Workflow</strong></h3><h4><strong>Artificial Intelligence and Automated Data Interpretation</strong></h4><p>The datasets generated by modern tandem MS platforms—particularly in omics applications—are too large and too complex for conventional manual review. AI-driven spectral deconvolution, automated peak integration, and AI-assisted hypothesis generation are now embedded in the software suites accompanying leading instruments. <a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/about/newsroom/presrel/2022/17feb-gp22004.html?srsltid=AfmBOop3warRIaEojXM2YyMML6RXfMIDzE-Wm0h-SiKkkocBeeET2m7u"><strong>Agilent’s acquisition of Virtual Control’s ACIES </strong></a>software specifically to automate LC–MS and GC–MS data analysis is emblematic of this direction.</p><p>For laboratory managers, AI integration means smaller specialized teams can operate high-throughput multi-analyte workflows—but it also means that the front-end sample preparation must be even more reproducible, since algorithmic interpretation amplifies inconsistencies introduced upstream.</p><h4><strong>Online SPE Coupling and “Chromatography Without Walls”</strong></h4><p>A significant trend is the integration of solid-phase extraction directly into the HPLC flow path—so-called online SPE–HPLC coupling. Systems that combine extraction and chromatographic separation in a single analytical instrument reduce manual transfer steps, minimize the risk of sample loss or contamination, and dramatically increase throughput. For analytes at very low concentrations, online SPE provides the on-column concentration capability that traditional offline preparation achieves with manual evaporation steps.</p><p>That said, offline sample preparation—including <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5392"><strong>nitrogen-assisted evaporation</strong></a> under controlled conditions, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2407"><strong>liquid–liquid extraction</strong></a>, and protein precipitation—retains significant advantages in flexibility, matrix handling, and the ability to process sample volumes that exceed online system capacity. The two approaches are increasingly complementary rather than competitive in well-designed analytical laboratories.</p><h4><strong>High-Purity Solvents and Reference Materials</strong></h4><p>As detection limits push further into the femtogram range and regulatory methods demand demonstrable blank performance, the quality of analytical consumables—mobile phase solvents, derivatization reagents, reference standards—has moved from background consideration to front-of-mind. Method validation in regulated environments now routinely requires vendor certification of solvent purity at a level that directly interfaces with instrument performance.</p><h3><strong>The Ever-Present Need for Sample Evaporation</strong></h3><p>As LC–MS/MS methods push detection limits lower, the analytical burden shifts increasingly upstream. The quality of the concentration, cleanup, and reconstitution steps preceding injection determines whether the instrument’s theoretical sensitivity is achievable in practice.</p><p><strong>Several specific developments are particularly relevant:</strong></p><ul><li><strong>ADC and gene therapy characterization workflows</strong> require gentle, low-temperature evaporation that preserves protein structure and prevents aggregation prior to LC–MS/MS. Nitrogen evaporation under controlled conditions is the preferred approach.</li><li><strong>PFAS trace analysis</strong> demands evaporation systems constructed from PFAS-inert materials, with rigorous attention to avoiding fluoropolymer surfaces throughout the sample path.</li><li><strong>High-throughput pharmaceutical QC</strong> driven by reshoring demands parallel processing capability—multi-position evaporators that maintain consistent flow and temperature across all positions simultaneously.</li><li><strong>Multi-omics and metabolomics workflows</strong> generate large sample batches that benefit from automated, walk-away evaporation with programmable endpoints to ensure reproducible final volumes across a cohort.</li></ul><p>Tandem chromatography–mass spectrometry is not merely growing; it is becoming structurally embedded in the analytical workflows of every major regulated industry. The convergence of biopharma complexity, PFAS regulatory mandates, AI-enabled data analysis, and pharmaceutical reshoring is creating a multi-year demand cycle that will require laboratories to invest not only in instruments, but in the entire sample preparation ecosystem that makes those instruments perform.</p><p>For analytical chemists, the practical takeaway is this: as mass spectrometry sensitivity continues to advance, the sample preparation step becomes the binding constraint on method performance. Whether you are developing a new PFAS method to meet EPA 1633, characterizing an ADC’s drug-to-antibody ratio, or running a 500-sample metabolomics cohort overnight, the reliability and cleanliness of your concentration and cleanup workflow determines the quality of every data point that follows.&nbsp;</p>

The Continued Rise of Tandem Chromatography–Mass Spectrometry

<h3><span><strong>A Practical Guide to Getting the Most from Syringe Filters: Tips, Tricks, and Common Pitfalls</strong></span></h3><p><span><strong>Syringe filters play a crucial role in chromatography and many other laboratory applications by removing particulate matter before analysis. Proper sample filtration helps protect analytical instruments, extends column lifetime, and improves data quality. However, selecting an unsuitable filter—or using one incorrectly—can introduce contamination, reduce filtration efficiency, or even compromise analytical results. The following recommendations will help you avoid common mistakes and ensure reliable filtration every time.</strong></span></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_3_150e8c1c2b.webp" alt="KNAUER: Avoiding Common Syringe Filter Mistakes" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_3_150e8c1c2b.webp 133w," sizes="100vw" width="1276" height="1496"></p><h4><span><strong>1. Improper Filter Handling</strong></span></h4><p><span>Using excessive force during filtration or attempting to reuse disposable syringe filters can damage the membrane and increase the risk of sample contamination.</span></p><ul><li><span><strong>Solution:</strong> Apply slow, even pressure throughout the filtration process and always dispose of single-use filters after one use. If the flow rate decreases noticeably, replace the filter instead of applying additional force.</span></li></ul><h4><span><strong>2. Selecting an Inappropriate Pore Size</strong></span></h4><p><span>Using the wrong pore size may either fail to remove unwanted particles or cause the membrane to clog prematurely, reducing filtration efficiency.</span></p><ul><li><span><strong>Solution:</strong> A 0.45 µm membrane is generally suitable for routine particulate removal, while a 0.22 µm membrane is recommended for finer filtration and bacterial removal. Samples with higher viscosity may require a pre-filter to prevent rapid clogging. It is also important to consider the intended analytical technique. For example, 0.22 µm filters are typically preferred for UHPLC and LC-MS applications, whereas 0.45 µm filters are often sufficient for conventional HPLC analyses.</span></li></ul><h4><span><strong>3. Choosing the Wrong Membrane Material</strong></span></h4><p><span>Different membrane materials exhibit different chemical resistance. Using an incompatible membrane may lead to degradation of the filter, sample contamination, or complete filtration failure.</span></p><ul><li><span><strong>Solution:</strong> Always verify solvent compatibility before filtration. PTFE membranes are an excellent choice for organic solvents, while PES and nylon membranes are better suited to aqueous samples. If compatibility is uncertain, perform a small-scale trial before filtering valuable samples.</span></li><li><span><strong>Pro Tip:</strong> For additional guidance, see our blog article <strong>"How to Choose the Right Membrane for your Syringe Filter"</strong>, which provides a detailed comparison of membrane materials and their recommended applications.</span></li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_2_e47021fb11.jpg" alt="KNAUER Sepapure® Syringe Filters are available with multiple membrane materials, each identified by a dedicated color code for quick and reliable selection." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_2_e47021fb11.jpg 245w," sizes="100vw" width="1580" height="902"></p><h4><span><strong>4. Ignoring Filter Capacity</strong></span></h4><p><span>Using a filter with insufficient capacity can result in rapid membrane blockage, increasing filtration time and reducing laboratory productivity.</span></p><ul><li><span><strong>Solution:</strong> When filtering larger sample volumes, choose high-capacity syringe filters or introduce a pre-filtration step. Never force liquid through a clogged membrane, as doing so may damage the filter and negatively affect sample quality.</span></li></ul><h4><span><strong>5. Overlooking Sample Adsorption</strong></span></h4><p><span>Certain membrane materials may adsorb analytes of interest, leading to lower recoveries and potentially affecting quantitative results.</span></p><ul><li><span><strong>Solution:</strong> For protein samples or other adsorption-sensitive analytes, select membranes with low binding characteristics, such as nylon or glass fiber, whenever appropriate. Performing a small recovery test before routine analysis can help identify potential analyte losses.</span></li></ul><h4><span><strong>6. Failing to Optimize Filtration Performance</strong></span></h4><p><span>Slow filtration is more than just an inconvenience—it often indicates that the filtration conditions are not optimal.</span></p><ul><li><span><strong>Solution:</strong> If filtration becomes unusually slow, investigate possible causes such as membrane clogging, excessive sample viscosity, or an unnecessarily small pore size. Depending on the sample, dilution or sequential filtration using progressively finer filters may significantly improve performance.</span></li></ul><h4><span><strong>Final Thoughts</strong></span></h4><p><span>Selecting the appropriate syringe filter is a straightforward process, but overlooking small details can have a significant impact on analytical performance. Choosing the correct membrane material, pore size, and filtration strategy helps improve laboratory efficiency, protects chromatography systems and columns, and contributes to accurate, reproducible analytical results.</span></p><p><span>With the right syringe filter and proper filtration technique, you can minimize sample preparation problems and maximize confidence in every analysis.</span></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_4_983a15e289.jpg" alt="KNAUER: Sepapure® Syringe Filter Selection" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_4_983a15e289.jpg 245w," sizes="100vw" width="1160" height="627"></p><p><span><strong>Happy filtering!</strong></span></p>

Avoiding Common Syringe Filter Mistakes

News from LabRulezLCMS Library - Week 27, 2026

Article

Product

Application

Academy

Poster

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

Separation Science

Agilent Technologies

Technology Networks

Bruker

Thermo Fisher Scientific

SCIEX

Waters Corporation

<h4><strong>Virtual event: Pharma conclave series 2024</strong></h4><p>SCIEX offers the platform for the experts to take the stage and drive technological progress</p><p><strong>Welcome to Pharma conclave series 2024</strong> – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.</p><p>From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.</p><ul><li>May 16 <strong>Event 1: Pharma omics</strong></li><li>September 17 <strong>Event 2: Impurities</strong></li><li>October 23-24 <strong>Event 3: Pharma</strong></li></ul><p><strong>10:00 a.m.–12:00 p.m. CET</strong></p><h3><strong>Event 3: Pharma</strong></h3><p><strong>The pharma connection</strong></p><p>From discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.</p><p>Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.</p><h3><strong>Day 1</strong></h3><h5><strong>10:00 - 10:30 - Metabolomics screening kits for use in clinical trials</strong></h5><ul><li>Heike Wiese, Nuvisan</li></ul><h5><strong>10:30 – 11:00&nbsp;- Sphingolipid biomarkers in neurodegenerative drug development</strong></h5><ul><li>Jose Carlos Gonzalez, AMSbiopharma</li></ul><h5><strong>11:00 – 11:30 - Parallel setup of a series of micro LC methods, coupled with the low-resolution mass spec (API7500) for &nbsp;TG2 inhibitors</strong></h5><ul><li>Davide Massari and Chiara Olmi, ERBC Group</li></ul><h5><strong>11:30 – 12:00&nbsp;- PFAS analysis and mass spectrometry: Beyond environmental, food and packaging. What about cosmetic and pharmaceutical products?</strong></h5><ul><li>Emiliano De Dominicis, Merieux</li></ul><blockquote><p><strong>Presenter:</strong> Bruno Manadas, PhD</p></blockquote><blockquote><p>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</p></blockquote><blockquote><p><strong>Presenter:</strong> Dorte Bekker-Jensen</p></blockquote><blockquote><p>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</p></blockquote><blockquote><p><strong>Presenter:</strong> Stefan Ledinger</p></blockquote><blockquote><p>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</p></blockquote><blockquote><p><strong>Presenter:</strong> Markus Langsdorf</p></blockquote><blockquote><p>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</p></blockquote>

Pharma conclave series 2024: Pharma (Day1)

From discovery to QA/QC. The process to bring a new treatment to the patients.

<h4><strong>Virtual event: Pharma conclave series 2024</strong></h4><p>SCIEX offers the platform for the experts to take the stage and drive technological progress</p><p><strong>Welcome to Pharma conclave series 2024</strong> – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.</p><p>From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.</p><ul><li>May 16 <strong>Event 1: Pharma omics</strong></li><li>September 17 <strong>Event 2: Impurities</strong></li><li>October 23-24 <strong>Event 3: Pharma</strong></li></ul><p><strong>10:00 a.m.–12:00 p.m. CET</strong></p><h3><strong>Event 3: Pharma</strong></h3><p><strong>The pharma connection</strong></p><p>From discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.</p><p>Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.</p><h3><strong>Day 2</strong></h3><h5><strong>10:00 - 10:30&nbsp;- Metabolomics: From target engagement to metabolic phenotyping. Applications in drug discovery</strong></h5><ul><li>Filippos Michopoulos, Astrazeneca</li></ul><h5><strong>10:30 - 11:00&nbsp;- Development of an LC-MS Method to Quantify Endogenous Urea in Mouse Plasma and BAL.</strong></h5><ul><li>Benjamin Smith, Cyprotex</li></ul><h5><strong>11:00 - 11:30&nbsp;- Optimization of extraction &amp; LC-MS conditions for the bioanalysis of antibody drug conjugates with diverse chemistries</strong></h5><ul><li>John Perkins, KCAS</li></ul><h5><strong>11:30 - 12:00&nbsp;- Preparation of rodent whole blood and plasma microsamples for LC-MS/MS bioanalysis in toxicology studies</strong></h5><ul><li>Birgitte Støvring, Scantox</li></ul><blockquote><p><strong>Presenter:</strong> Bruno Manadas, PhD</p></blockquote><blockquote><p>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</p></blockquote><blockquote><p><strong>Presenter:</strong> Dorte Bekker-Jensen</p></blockquote><blockquote><p>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</p></blockquote><blockquote><p><strong>Presenter:</strong> Stefan Ledinger</p></blockquote><blockquote><p>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</p></blockquote><blockquote><p><strong>Presenter:</strong> Markus Langsdorf</p></blockquote><blockquote><p>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</p></blockquote>

Pharma conclave series 2024: Pharma (Day 2)

<p><strong>We invite you to join a hybrid event on October 15<sup>th</sup> to explore the latest solutions and workflows for overcoming environmental and food contaminant testing challenges.</strong></p><p>This event will be broadcast live from the laboratory at Thermo Fisher Scientific Customer Solutions Center (CSC) in Paris. You can join in person at one of our many 'satellite' venues worldwide, where we will offer an extended agenda, or participate remotely through the live broadcast.</p><p>During the live stream broadcast, you will meet our Customer Solution Centre specialist team and leading industry expert, John Quick, as they discuss innovative solutions to meet the ever-evolving testing demands. There will be plenty of time to ask these experts your questions.</p><p>The following sessions will be streamed all over Europe and beyond:</p><ul><li><strong>Detecting PFAS in drinking water to meet regulations across Europe</strong> – New automated sample preparation high-resolution MS solution to achieve parts per trillion detection limits.<br><i>Aristide Ganci,&nbsp;Senior Product Application Specialist, Thermo Fisher Scientific; Valérie Thibert, Senior Product Application Specialist, Thermo Fisher Scientific; Bénédicte Gauriat, Senior Product Application Specialist, Thermo Fisher Scientific</i></li><li><strong>New ready-to-go pesticide residue solution for faster, more confident results</strong><br><i>Zoe Julian, Product Marketing Specialist, Manager; Bénédicte Gauriat, Senior Product Application Specialist, Thermo Fisher Scientific; Julie Moriceau, Senior Product Application Specialist, Thermo Fisher Scientific</i></li><li><strong>Low-level contaminant testing in environmental water matrices</strong>&nbsp;– High-Resolution Accurate Mass GC-MS approach to meet future regulations<br><i>John Quick, Principal Scientist, ALS Environmental Ltd</i></li></ul><p>After the live stream concludes, 'satellite' locations offer a unique program onsite. Take this unique opportunity to connect with industry professionals, or join us to explore, network, and collaborate on your future projects. Scroll below to the venue of your choice to discover the individual agenda.</p><p>Participation is free of charge, registration is required.</p><p>For any questions about this event or regarding your registration, please email <a href="mailto:CMDEvents@thermofisher.com">CMDEvents@thermofisher.com</a>.</p><h3><strong>Preliminary agenda</strong></h3><h5><strong>10:15 Live streaming of this event to ‘satellite’ locations and online audience</strong></h5><h5><strong>10:30 Introduction</strong></h5><ul><li>Jeff Stubbs (Business Development Manager, Environment and Food Safety, Thermo Fisher Scientific)</li></ul><h5><strong>10:55 Detecting PFAS in drinking water to meet regulations across Europe - New automated sample preparation high-resolution MS solution to achieve ppt detection limits</strong></h5><ul><li>A Ganci, V Thibert and B Gauriat (Senior Product Application Specialists, Thermo Fisher Scientific)</li></ul><h5><strong>11:35 Break</strong></h5><h5><strong>12:05 New ready-to-go pesticide residue solution for faster, more confident results</strong></h5><ul><li>Z Julian, Product Marketing, B Gauriat, and J Moriceau (Senior Product Application Specialists Thermo Fisher Scientific)</li></ul><h5><strong>12:45 Low-level contaminant testing in environmental water matrices – high-resolution GCMS approach to meet future regulations</strong></h5><ul><li>John Quick (Principal Scientist, ALS Environmental Ltd)</li></ul><h5><strong>13:15 Closing comments</strong></h5><h5><strong>13:30 End of live streaming</strong></h5><div><div container-id="cq-colctrl-lt7" comp-id="B1"><div><div><div><div><div><div><blockquote><h3>How to attend?</h3><p>3 ways of attending:</p><p><strong>Customer Solution Centre (in-person event):&nbsp;</strong><br>Join the heart of the event at our Customer Solution Center in Paris, where the main agenda will be hosted and live-streamed worldwide to our ‘Satellite’ locations and our audience.</p><p><strong>Join a ‘Satellite’ location (in-person event):&nbsp;</strong><br>Our in-person ‘Satellite’ events will broadcast the main agenda live-streamed from our Customer Solution Center in Paris and supplement the day with local presentations, lab tours, or workshops. Take this opportunity to meet your Thermo Fisher representatives and industry experts from the region. Discover the individual agenda for your ‘Satellite’ location of interest.</p><p><strong>Online attendees (remote):&nbsp;</strong><br>Unable to travel to a ‘Satellite’ event? Not a problem! You can register to attend conveniently online from your desk or anywhere else through the live stream from our Customer Solutions Center in Paris.</p></blockquote></div></div></div></div></div></div></div></div>

Thermo Scientific: Solutions for environmental and food contaminant testing

Solutions for environmental and food contaminant testing

New and advancing workflows to meet and exceed European regulations.

<p><strong>Clinical blood analysis is crucial for monitoring health and diagnosing diseases, with blood-based biomarkers playing a key role.</strong></p><p>However, current detection methods often lack sufficient coverage. Mass spectrometry-based proteomics provides a robust solution for in-depth plasma proteome analysis, but precise sample preparation is essential.</p><p>This webinar will guide you on maximizing plasma proteome coverage and optimizing sample preparation, whether using plasma or serum. Dr. König and Dr. Wendt will discuss developing an optimized, automated workflow for comprehensive plasma biomarker discovery, showcasing results from two complementary techniques: LC-MS and Olink.</p><h4>Attend this webinar to:</h4><ul><li><strong>Discover how to efficiently prepare blood-derived samples, including plasma and serum</strong></li><li><strong>Explore how to implement a fully automatable, reproducible and standardized plasma workflow with scalable throughput</strong></li><li><strong>Achieve comprehensive plasma proteome characterization, addressing the dynamic range challenge for deeper insights</strong></li><li><strong>Learn to apply LC-MS-based proteomics combined with affinity-based methods to discover novel disease biomarkers</strong></li></ul><blockquote><p><strong>Presenter: </strong>Dr. Ann-Christine König (Proteomics Core Facility Manager, Helmholtz Zentrum Munich)<br><br><strong>Presenter:&nbsp;</strong>Dr. Fabian Wendt (Product and Application Manager, Mass Spectrometry, Tecan)</p></blockquote>

Technology Networks: Unlocking the Plasma Proteome: Advanced Profiling and Biomarker Discovery

Unlocking the Plasma Proteome: Advanced Profiling and Biomarker Discovery

Maximizing plasma proteome coverage and optimizing sample preparation, whether using plasma or serum.

Unlocking the Plasma Proteome: Advanced Profiling

<p><strong>Join us as we introduce our path to visualize molecules from tissue at single cell resolution using DESI MS imaging, with the commercial DESI XS ionization source coupled to Xevo G3 QToF Mass Spectrometer.</strong></p><p>This webinar will explain how to easily transition to high resolution MS Imaging with a traditional entry level commercial DESI MS imaging toolkit.</p><h4>Learn how to:</h4><ul><li><strong>Understand High spatial resolution MS Imaging is now accessible to all labs and applications</strong></li><li><strong>Access single cell DESI Imaging with the combination of DESI XS and Xevo G3 QToF</strong></li><li><strong>Leverage both high sensitivity and high speed of acquisition with the Xevo G3 QToF without compromising MS Imaging data quality</strong></li><li><strong>Utilize HDI 1.8 Imaging software for microscope mode analysis for effective use of time in MS Imaging experiments</strong></li><li><strong>Obtain comprehensive and detailed spatial information with limited sample preparationAdd MSI analysis into a multi-modal imaging workflow with ease</strong></li></ul><blockquote><p><strong>Presenter:&nbsp;</strong>Dr Jamie Reilly (Postdoctoral Researcher, University of Galway)</p><p>Dr. Jamie Reilly is a postdoctoral researcher in NUIG Galway. Prior to joining the CELLIMAGE project, Jamie undertook his PhD in Regenerative Medicine in REMEDI, where he used bioinformatics to analyze molecular pathways in cellular and animal models of autism spectrum disorder (ASD). Jamie attended Trinity College Dublin (TCD) for his undergraduate degree in Genetics, and has a Masters in Biotechnology from Queens University Belfast.</p><p><strong>Presenter:&nbsp;</strong>Dr. Mark Towers (Principal Scientist - MS Technology, Waters)</p><p>Mark Towers gained his PhD from the University of Reading in Bioanalytical chemistry on the Development of applications and techniques for UV-Liquid-MALDI-MS. Mark joined Waters over 10 years ago into the Scientific operations team as a senior scientist, working on high resolution mass spectrometry and imaging.</p><p>Mark’s primary area of focus has been surface analysis by desorption electrospray ionisation (DESI) with over 7 years experience and matrix assisted laser desorption ionisation for over 14 years, principally but not limited to tissue sections for the detection and distribution mapping of a wide range of molecules.</p><p><strong>Presenter: </strong>Dr. Joanne Ballantyne (Director, MS Imaging program, Waters Corporation)</p><p>Joanne completed a PhD in Mass Spectrometry at UMIST in Manchester 2002, in collaboration with UK Ministry of Defence's Science and Technology Lab (Dstl). This was followed by a post-doc at NIH in Bethesda, USA, working in OMICS for the NIMH. After returning to the UK, and time as a MALDI applications chemist at Shimadzu Biotech, Joanne joined Waters Corporation in 2007 as a member of the OMICS Application team in Manchester and progressed to managing the team. Following this Joanne spent a number of years in Business Development and Field Marketing for discovery applications in the Northern European region. At the end of 2018 Joanne joined the Product Management group with responsibility for the SYNAPT and MS Imaging technologies. After gaining ILM7 accreditation in strategic leadership, Joanne is now Director of the MS Imaging program.</p></blockquote>

Waters Corporation: Towards Single Cell Imaging Session 1

Towards Single Cell Imaging Session 1

How to easily transition to high resolution MS Imaging with a traditional entry level commercial DESI MS imaging toolkit.

<p><strong>This session will provide a comprehensive introduction to the user interface, ensuring you can navigate with ease. Discover the various acquisition modes available and learn how to select the best one for your specific application.</strong></p><p>Additionally, we will explore the innovative Intelligent Reflex feature, highlighting its benefits in boosting your productivity.</p><p>Whether you’re new to MassHunter or looking to refine your skills, this webinar is designed to enhance your understanding and efficiency.</p><blockquote><p><strong>Presenter:</strong> Christian Hegmanns (Application Specialist LC/MS, Agilent Technologies, Waldbronn, Germany)</p><p>Christian Hegmanns is a state-certified food chemist and works at Agilent as an LC/MS application specialist.</p><p>With over 10 years of experience in the field of instrumental analysis, Christian develops customer-oriented solutions for a variety of applications with a focus on food analysis.</p></blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Acquisition Q-TOF Part I – Basic Overview

Join us for an insightful webinar where we delve into the essentials of MassHunter Acquisition Q-TOF. 

<p><strong>This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.</strong></p><p>We will delve into various MS acquisition modes, including MS only, All Ions (QRAI), Auto MS/MS (directed MS/MS; targeted MS/MS), and PRM mode.</p><p>Learn how to fine-tune method settings to enhance your data quality and achieve the best analytical results. Whether you’re a seasoned user or new to QTOF, this session will provide valuable insights to elevate your mass spectrometry.</p><blockquote><p><strong>Presenter:</strong> &nbsp;Stefan Schaebler (Application Specialist LC/MS, Agilent Technologies)</p><p>Stefan completed his PhD in Biology, specializing in LC-MS-based lipidomics and metabolomics. Following his doctoral studies, he joined Agilent Technologies as an LC/MS Application Specialist. In this role, Stefan focuses on small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</p></blockquote>

MassHunter Acquisition Q-TOF Part II – Advance Settings

Join us for an in-depth exploration of advanced settings in MassHunter Acquisition for Q-TOF systems.

<div><div><p><strong>Therapeutic synthetic oligonucleotides represent unique analytical challenges in late-stage development. To meet the stringent regulatory requirements, highly specific and sensitive methods such as liquid chromatography-mass spectrometry (LC/MS) must be used. However, neither chromatography nor mass spectrometry data systems have the capabilities, both in function and in data integrity, for the typical QC analyst end user to run a highly complex method such as purity, assay, and impurity profiling for therapeutic oligos such as anti-sense oligonucleotides.</strong></p><p>In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS. This application streamlines the analytical workflow by using a fit-for-purpose user interface while leveraging existing data integrity and compliance architecture within OpenLab CDS.</p><h4>By attending this webinar, you will:</h4><ul><li><strong>Understand the fundamentals of ion-pair reversed-phase LC/MS for oligonucleotides</strong></li><li><strong>Discover how a single quadrupole detector is used for impurity profiling of anti-sense oligonucleotides</strong></li><li><strong>Learn how fit-for-purpose software for LC/MS analysis in QC lot release can save time and enhance quality</strong></li></ul><h5>Who should attend</h5><ul><li>Analytical chemists interested in cutting-edge software for large molecule late-stage development</li><li>Analytical research and development labs interested in developing robust methods for single-stranded oligo therapeutics</li><li>Process scientists who rely on in-process control purity results to optimize synthesis and purification for oligos</li><li>Quality assurance and quality control personnel supporting oligo testing labs</li></ul><blockquote><p><strong>Presenter:</strong> Brian Rivera (Software Product Manager, Agilent Technologies)</p><p>Brian Rivera is a software product manager at Agilent Technologies with 20 years of experience in HPLC analysis of large molecules.</p></blockquote></div></div>

Separation Sciences: Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS.

Oligonucleotide QC with Software Designed for the Job

<p id="isPasted"><strong>Biotherapeutics offer targeted therapies for treating a wide range of diseases with greater specificity and efficacy. However, unlike traditional small-molecule drugs, biotherapeutics are typically larger and more complex, requiring advanced techniques for their production, purification, and characterization.</strong></p><p>Therapeutic proteins, first introduced many years ago, have continually advanced in complexity. Since the introduction of monoclonal antibodies, we now have antibody drug conjugates, bispecific antibodies, fragments and fusion proteins, all of which are in various stages of development.&nbsp;</p><p>To keep pace with biotherapeutics advances, analytical techniques must also advance.&nbsp;</p><h5><strong>In this webinar, we will present chromatography findings on:</strong></h5><ul><li><strong>New workflows for intact and peptide mapping characterization of proteins</strong></li><li><strong>Advanced column chemistries for charge variant analysis with pH and salt gradients&nbsp;</strong></li><li><strong>Rapid desalting SEC column for high throughput analysis, ADC analysis with HIC and reversed phase chemistries</strong></li><li><strong>New digestion workflows coupled to a new peptide mapping column for sequence verification and post translation modification analysis</strong></li></ul><p>This live webinar will be an excellent opportunity to boost your R&amp;D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies. Dr. Ken Cook will be presenting and answering your questions live.</p><p>With over 20 years of innovation, Thermo Fisher Scientific is a leader in biomolecule separation and characterization, supported by a wealth of published research.</p><p id="isPasted"><strong fr-original-style="">Who should attend?&nbsp;</strong></p><ul><li><strong fr-original-style="">Pharmaceutical and Biotech Researchers</strong>: Researchers involved in the development and characterization of biotherapeutics and gene therapies, including those working with therapeutic proteins.</li><li><strong fr-original-style="">Quality Control (QC) Analysts</strong>: Analysts responsible for ensuring the quality and consistency of biotherapeutic products, who will benefit from advanced methods in characterization and validation.</li><li>&nbsp;<strong fr-original-style="">R&amp;D Managers</strong>: Managers who oversee research and development teams working with biotherapeutics, looking to enhance their workflows and methodologies.</li></ul><blockquote><p><strong>Presenter:</strong> Dr. Ken Cook (Application Scientists Manager, Thermo Fisher Scientific)</p><p>Dr. Ken Cook began his career in academia as a Biochemistry lecturer focused on protein chemistry and metabolism. With over 30 years of industry experience at Dionex, and later Thermo Fisher Scientific, his vast knowledge supporting and developing solutions within chromatography has established him as a bio-separations expert.</p><p>Currently, Dr. Cook focuses on supporting and developing solutions for bio-pharmaceutical applications, particularly in the characterization of protein and oligonucleotide-based biotherapeutics. His work involves ongoing collaborations with both the biopharmaceutical industry and academic institutions.</p><p>His expertise includes peptide mapping using LC/HRMS, charged variant analysis with novel MS coupling, glycan analysis, aggregate analysis, and on-line process monitoring. He also has a growing interest and notable success in gene therapy characterization.</p><p>Given his immense experience, it is an honour to have Dr Cook share his knowledge.</p></blockquote>

Thermo Fisher Scientific: Innovations in Protein Characterization

Innovations in Protein Characterization

Boost your R&D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies.

<div><div><div><p><strong>Alithea Biotechnology was founded in 2019 by Fanny Giannou and Tim Fugmann to support Biopharma globally on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery.</strong></p><p>In addition, HLA-Compass is Alithea's cloud-accessible HLA peptide database featuring the measurement of a total of 1.4 Million HLA peptides in 4160 healthy tissue, tumor tissue and cancer cell line samples for target validation and off-target toxicity prediction.</p><h5><strong>Why to join this webinar:</strong></h5><ul><li><strong>The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample</strong></li><li><strong>Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process</strong></li><li><strong>The time is ripe to bring immunopeptidomics into clinical routine</strong></li></ul><blockquote><p><strong>Presenter:</strong> Tim Fugmann, Ph.D. (Chief Scientific Officer and Co-Founder, Alithea Biotechnology GmbH, Berlin, Germany)</p><p>Tim Fugmann got his Ph.D. from ETH Zurich, on mass-spectrometric discovery of antibody targets and disease biomarkers. Later, he was leading the target discovery efforts at Philochem, before moving to the Max-Delbrueck-Centrum for Molecular Medicine in Berlin. He was later appointed professor for MS-based proteomics at JLU Giessen. In 2019 he co-founded Alithea Bio UG, which is focusing on immunopeptidomics, a topic which Tim Fugmann studied since 2012.</p></blockquote></div></div></div>

Bruker: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery.

LCMS webinars focusing on LC/HRMS - page 24